spiro[1H-3,1-benzoxazine-4,4'-piperidine]-2-one

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (400 mg, 1.83 mmol) was suspended in anhydrous 1,2-dichloroethane (8.0 mL) and treated with 1,4-cyclohexanedione mono-ethylene ketal (viia) (429 mg, 2.75 mmol), glacial acetic acid (220 mg, 3.66 mmol), and sodium triacetoxyborohydride (776 mg, 3.66 mmol). The reaction flask was flushed with nitrogen and stirred for 60 hours at room temperature. The reaction was diluted with dichloromethane (25 mL), quenched with 1.0 N NaOH (10 mL), and stirred at room temperature vigorously for 30 minutes. The layers were separated and the aqueous layer was extracted once with dichloromethane (10 mL). The pooled organic layers were washed with water (1×25 mL) and saturated brine (1×25 mL), dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure to afford crude 1′-(1,4-dioxaspiro[4.5]decan-8-yl)spiro[benzo[d][1,3]oxazine-4,4′-piperidin]-2(1H)-one (viiib) as a white solid. LC/MS m/z 359.2 [M+H]+, retention time 1.61 min (RP-C18, 10-99% CH3CN/0.05% TFA). The reaction flask was flushed with nitrogen The reaction was diluted with dichloromethane (25 mL) quenched with 1.0 N NaOH (10 mL) stirred at room temperature vigorously for 30 minutes The layers were separated the aqueous layer was extracted once with dichloromethane (10 mL) The pooled organic layers were washed with water (1×25 mL) and saturated brine (1×25 mL) dried over Na2SO4 filtered The filtrate was concentrated under reduced pressure

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (410 mg, 1.88 mmol) was dissolved in anhydrous 1,2-dichloroethane (10 mL) and treated with tert-butyl 4-oxopiperidine-1-carboxylate (via) (562 mg, 2.82 mmol), glacial acetic acid (226 mg, 3.76 mmol) and sodium triacetoxyborohydride (797 mg, 3.76 mmol). The reaction was stirred under nitrogen at room temperature for 72 hours. The reaction was concentrated under reduced pressure and the residue partitioned between 1.0 N HCl (50 mL) and diethyl ether (25 mL). The aqueous layer was separated and washed with diethyl ether (2×25 mL), basified with 1.0 N NaOH (aq) and extracted with dichloromethane (3×50 mL). The pooled extracts were washed with saturated brine, dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo to afford tert-butyl 4-(2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,4′-piperidine]-1′-yl)piperidine-1-carboxylate (vib) as a crystalline white solid. LC/MS m/z 402.2 [M+H]+, retention time 1.84 min (RP-C18, 10-99% CH3CN/0.05% TFA). The reaction was concentrated under reduced pressure the residue partitioned between 1.0 N HCl (50 mL) and diethyl ether (25 mL) The aqueous layer was separated washed with diethyl ether (2×25 mL) extracted with dichloromethane (3×50 mL) The pooled extracts were washed with saturated brine dried over Na2SO4 filtered The filtrate was concentrated in vacuo

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (410 mg, 1.88 mmol) was dissolved in anhydrous 1,2-dichloroethane (10 mL) and treated with tert-butyl 4-oxopiperidine-1-carboxylate (via) (562 mg, 2.82 mmol), glacial acetic acid (226 mg, 3.76 mmol) and sodium triacetoxyborohydride (797 mg, 3.76 mmol). The reaction was stirred under nitrogen at room temperature for 72 hours. The reaction was concentrated under reduced pressure and the residue partitioned between 1.0 N HCl (50 mL) and diethyl ether (25 mL). The aqueous layer was separated and washed with diethyl ether (2×25 mL), basified with 1.0 N NaOH (aq) and extracted with dichloromethane (3×50 mL). The pooled extracts were washed with saturated brine, dried over Na2SO4 and filtered. The filtrate was concentrated in vacuo to afford tert-butyl 4-(2-oxo-1,2-dihydrospiro[benzo[d][1,3]oxazine-4,4′-piperidine]-1′-yl)piperidine-1-carboxylate (vib) as a crystalline white solid. LC/MS m/z 402.2 [M+H]+, retention time 1.84 min (RP-C18, 10-99% CH3CN/0.05% TFA). The reaction was concentrated under reduced pressure the residue partitioned between 1.0 N HCl (50 mL) and diethyl ether (25 mL) The aqueous layer was separated washed with diethyl ether (2×25 mL) extracted with dichloromethane (3×50 mL) The pooled extracts were washed with saturated brine dried over Na2SO4 filtered The filtrate was concentrated in vacuo

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (22 mg, 0.10 mmol) was dissolved in anhydrous 1,2-dichloroethane (750 μL) in a scintillation vial and treated with 3-methylbutanal (va) (9 mg, 0.10 mmol), followed by sodium triacetoxyborohydride (30 mg, 0.14 mmol). The reaction was stirred at room temperature for 1 hour, then quenched with methanol (500 μL) and stirred at room temperature for an additional 30 minutes. The reaction was filtered (Whatman 0.45 μm PTFE) and subjected to reverse-phase HPLC purification [2-99% CH3CN gradient over 13 min with 0.1% TFA (aq), 35 mL/min, 1.0 mL injected] to provide 1′-isopentylspiro[benzo[d][1,3]oxazine-4,4′-piperidin]-2(1H)-one (compound no. 76). LC/MS m/z 289.0 [M+H]+, retention time 1.55 min (RP-C18, 10-99% CH3CN/0.05% TFA). quenched with methanol (500 μL) stirred at room temperature for an additional 30 minutes The reaction was filtered (Whatman 0.45 μm PTFE) subjected to reverse-phase HPLC purification [2-99% CH3CN gradient over 13 min with 0.1% TFA (aq), 35 mL/min, 1.0 mL injected]

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: Spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (353 mg, 1.62 mmol) was dissolved in anhydrous 1,2-dichloroethane (10 mL) and treated with cycloheptanone (iiia) (273 mg, 2.43 mmol), followed by glacial acetic acid (195 mg, 3.24 mmol) and sodium triacetoxyborohydride (687 mg, 3.24 mmol). The reaction was stirred at room temperature under nitrogen for 90 hours. The reaction was diluted with dichloromethane (50 mL), quenched with 1.0 N NaOH (20 mL), and stirred vigorously at room temperature for 30 minutes. The layers were separated and the aqueous layer was extracted with dichloromethane (2×20 mL). The pooled organic layers were washed with (20 mL each) water and saturated brine; and dried over Na2SO4 and filtered. The filtrate was concentrated under reduced pressure to afford crude 1′-cycloheptylspiro[benzo[d][1,3]oxazine-4,4′-piperidin]-2(1H)-one as an off-white solid. quenched with 1.0 N NaOH (20 mL) stirred vigorously at room temperature for 30 minutes The layers were separated the aqueous layer was extracted with dichloromethane (2×20 mL) The pooled organic layers were washed with (20 mL each) water and saturated brine and dried over Na2SO4 filtered The filtrate was concentrated under reduced pressure

Conditions: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

Procedure: A scintillation vial was charged with bicyclo-[3.2.1]octan-3-one (iia) (31 mg, 0.25 mmol), spiro[4H-3,1-benzoxazine-4,4′-piperidin]-2(1H)-one (A4) (44 mg, 0.20 mmol), and anhydrous dimethoxyethane:dichloromethane (1.0 mL, 1:1 v/v). The mixture was treated with titanium tetraisopropoxide (171 mg, 0.60 mmol). The vial was flushed with nitrogen and stirred at room temperature for 60 hours. The reaction was then cooled in an ice water bath, quenched with methanol (1.0 mL) and treated with sodium borohydride (15 mg, 0.40 mmol). The reaction mixture was slowly warmed to room temperature, stirred for 1 hour, treated with 1.0 N NaOH (1.0 mL), diluted with methanol (2.0 mL), and stirred at room temperature for 15 min. The suspension obtained was centrifuged (3K rpm, 10 min), and the supernatant was filtered (Whatman 0.2 μm PTFE). The filtrate was concentrated under reduced pressure and the residue obtained dissolved in DMSO:methanol (1.5 mL, 1:1 v/v), filtered and subjected to reverse-phase HPLC purification [2-99% CH3CN gradient over 13 min with 0.1% TFA (aq), 35 mL/min, 1.0 mL injected] to provide 1′-(bicyclo[3.2.1]octan-3-yl)spiro[benzo[d][1,3]oxazine-4,4′-piperidin]-2(1H)-one (compound no. 67) as a TFA salt. LC/MS m/z 327.2 [M+H]+, retention time 1.80 min (RP-C18, 10-99% CH3CN/0.05% TFA). The vial was flushed with nitrogen The reaction was then cooled in an ice water bath quenched with methanol (1.0 mL) The reaction mixture was slowly warmed to room temperature stirred for 1 hour stirred at room temperature for 15 min The suspension obtained the supernatant was filtered (Whatman 0.2 μm PTFE) The filtrate was concentrated under reduced pressure the residue obtained methanol (1.5 mL, 1:1 v/v), filtered subjected to reverse-phase HPLC purification [2-99% CH3CN gradient over 13 min with 0.1% TFA (aq), 35 mL/min, 1.0 mL injected]